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Abstract
Background and Aim Primary percutaneous coronary inter-
vention (PCI) is the preferred treatment option for acute
myocardial infarction (MI). Off-site PCI reduces time-to-
treatment, which could potentially lead to enhanced clinical
outcomes. Therefore, we investigated whether off-site PCI
improves 5-year clinical outcomes compared with on-site PCI
and whether this is related to in-hospital 99mTc-sestamibi
single photon emission computed tomography (MIBI
SPECT) parameters.
Methods We describe the 5-year follow-up for a combined
endpoint of death or re-infarction in 128 patients with acute
MI who were randomly assigned to undergo primary PCI at
the off-site centre (n=68) or to transferral to an on-site
centre (n=60). Three days after PCI, MIBI SPECT was
performed to estimate infarct size. A multivariate Cox
regression model was created to study the relation between
MIBI SPECT parameters and long-term clinical outcomes.
Results After a mean follow-up of 5.8±1.1 years, 25 events
occurred. Off-site PCI significantly reduced door-to-balloon
time compared with on-site PCI (94±54 versus 125±
59 min, p=0.003). However, infarct size (17±15 versus
14±12%, p=0.34) and 5-year death or infarct rate (21%
versus 18%, p=0.75) were comparable between treatment
centres. With multivariate analysis, only Killip class ≥2 and
Q wave MI, but not scintigraphic data, predicted long-term
clinical outcomes.
Conclusion Off-site PCI reduced door-to-balloon time with
a comparable 5-year death or infarct rate. Parameters from
resting MIBI SPECT on day 3 after MI did not predict
long-term clinical outcomes.
Keywords Primary angioplasty .Myocardial
infarction . 99mTc-sestamibi SPECT. 5-Year clinical
outcome
Introduction
Primary percutaneous coronary intervention (PCI) is widely
accepted as the preferred reperfusion strategy to reduce infarct
size in patients with acute ST-segment elevation myocardial
infarction (STEMI) [1]. Trials comparing PCI in STEMI
patients presented to large community hospitals without on-
site cardiac surgical backup (off-site) versus PCI in a tertiary
interventional centre (on-site) have demonstrated that off-site
PCI is feasible and results in comparable short-term clinical
outcome [2,3]. Treatment in off-site centres results in a
significant reduction in time-to-treatment, which could
potentially lead to a reduction in infarct size by more timely
salvage of acutely jeopardised ischaemic myocardium [4–6].
In that respect, off-site PCI without transfer delay in STEMI
patients might even prove to be superior in limiting infarct
size [7,8].
We extended our earlier findings [9] and investigated
whether off-site PCI improves 5-year clinical outcomes
compared with on-site PCI and if this is related to in-
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hospital 99mTc-sestamibi single photon emission computed
tomography (SPECT) parameters.
Methods
Patients
This study describes the 5-year follow-up of STEMI patients
who, in a previous study, were randomly assigned to primary
PCI at the centre of presentation in a community hospital (off-
site, n=103) or to transferral to a remote tertiary centre with
surgical backup facilities (on-site, n=96) [6]. The in-hospital
outcomes in relation to 99mTc-sestamibi SPECT parameters
in 128 patients were described previously [9]. STEMI
patients who presented within 6 h after the onset of
symptoms, who were able to give informed consent and
did not require mechanical ventilatory assistance were
eligible for randomisation. Upon arrival at the cardiac care
unit and prior to randomisation, all patients were immedi-
ately treated with heparin, aspirin, nitroglycerin, and
abciximab, unless contraindicated. Standard treatment after
the PCI procedure included clopidogrel, β-blockers, aspirin,
ACE inhibitors, and statins, unless contraindicated. The
protocol was approved by the review board or ethics
committee of each hospital.
Of the original consecutive patient population (n=199),
128 patients consented to 99mTc-sestamibi SPECT imaging
3 days after the cardiac event. Failure to undergo 99mTc-
sestamibi SPECT was due to early death (5), emergency
CABG (1), previous myocardial infarction (MI; 11), unable
or unwilling to provide consent (42), no PCI was performed
and the absence of MI (4).
Scintigraphy
Rest gated myocardial perfusion images were acquired
approximately 1 h after an intravenous injection of
700 MBq 99mTc-sestamibi using SPECT. A dual-head
camera system, equipped with low-energy high-resolution
collimators, was used for myocardial imaging (Millennium
VG; GE Healthcare). Images were acquired in a 64×64
matrix with an acquisition time of 30 s per image. The
SPECT images were gated with eight frames per cardiac
cycle, and the RR time acceptance was set at 20%.
Transaxial slices were reconstructed via back projection
with a ramp filter, followed by a butterworth filter. Using
commercially available software, polar maps were created
of the relative distribution of tracer uptake throughout the
entire left ventricle (LV). Each polar map was normalised to
its individual maximum, and the defect size was defined as
<50% uptake area of the polar map and was subsequently
expressed as a percentage of the LV.
Follow-up
Information on survival status was obtained in all patients
in June 2009. Digital hospital records were reviewed for
all-cause mortality and enzymatically confirmed myocardial
re-infarction (re-MI), i.e. typical chest pain plus creatine
kinase-MB (CK-MB) or troponin I above the upper limit of
normal, i.e. >16 U/l and >0.45 μg/l, respectively.
Statistical Analysis
Data are expressed as mean±standard deviation (SD).
Frequencies were compared using Fisher’s exact test and
Student’s t test, and continuous variables were compared
using the independent t test. Comparison of multiple datasets
was performed using ANOVA, and specific differences were
identified by a Student’s t test corrected for multiple
comparisons with the Bonferroni adjustment.
The incidence of the combined endpoint over time was
evaluated according to the Kaplan–Meier method, and
differences between groups of patients were analysed with
the log-rank test. Univariate analysis of the combined
endpoint over time for baseline and 99mTc-sestamibi
SPECT parameters was performed using Cox proportional
hazard regression. Variables with a p value <0.5 in
univariate analysis were included in the multivariable
model so that no (measured) confounders were missed,
using the enter method. All analyses were performed using
SPSS 14 (SPSS Inc., Chicago, Illinois). A p value <0.05
was considered significant.
Results
The study cohort consisted of 128 patients, 93 (73%) were
men, and the mean age was 62±12 SD years. Baseline
characteristics and risk profile were comparable between
the 60 patients randomised to on-site and 68 patients
randomised to off-site PCI (Table 1). Mean follow-up was
5.8 years±1.1 SD. In this time frame, 15 re-MIs were
documented, and ten patients died. Kaplan–Meier analysis
demonstrated that there was no difference in long-term
outcomes and centre of randomisation, log rank 0.715
(Fig. 1).
Time to Treatment and Centre of Randomisation
The time lines revealed no difference in mean time from
onset of symptoms to presentation at the clinic between
groups. However, with a reduction of 31 min, the door-
to-balloon time was significantly shorter in the off-site
centre, although this did not result in a significant
reduction in pain onset time-to-treatment. Neither did
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this reduction of door-to-balloon time result in an
enzymatically smaller infarct size in off-site-treated
patients, peak CK-MB 204 vs. 161 U/l; p value, 0.11
(Table 2). In univariate and multivariate analyses, this was
further confirmed as none of the time line variables had a
significant relation with long-term clinical outcomes.
Scintigraphic Data and Centre of Randomisation
Various scintigraphic variables were analysed, but most
were comparable between on- and off-site PCI. However,
the summed thickening score (STS) was smaller in patients
randomised to on-site treatment, 14±12 versus 17±15 SD;
p value, 0.028 (Table 2).
Table 2 Comparison of centres regarding MIBI SPECT data and 5-year
clinical outcomes
On-site (n=60) Off-site (n=68) p
Death or infarct 11 (18%) 14 (21%) 0.75
LVESV (ml) 58±26 65±31 0.17
LVEDV (ml) 118±36 124±38 0.34
LVEF (%) 52±12 50±11 0.06
Infarct extent (%) 14±12 17±15 0.34
SRS 11±9.6 12±12 0.33
SMS 19±13 24±20 0.06
STS 14±12 17±15 0.028
Peak CK 1611±1838 1894±1609 0.35
Peak CK-MB (U/l) 161±136 204±160 0.11
Continuous data are presented as mean values±standard deviation.
Dichotomous data are presented as numbers and percentages
SPECT single photon emission computed tomography, LVESV left
ventricular end-systolic volume, LVEDV left ventricular end-diastolic
volume, LVEF left ventricular ejection fraction, SRS summed rest
score, SMS summed motion score, STS summed thickening score, CK
creatine kinase
Fig. 1 Difference in long-term follow-up between centres for the
combined endpoint of either death or re-infarction; log rank, 0.715
On-site (n=60) Off-site (n=68) p
Age (years) 64±11 61±12 0.62
Men 44 (73%) 49 (72%) 0.87
Diabetes mellitus 4 (7%) 2 (3%) 0.32
Smoker 24 (40%) 33 (49%) 0.59
Hypertension 15 (25%) 20 (29%) 0.58
Family history of CVD 27 (45%) 28 (41%) 0.66
Previous PCI 2 (3%) 2 (3%) 0.90
Previous CABG 3 (5%) 2 (3%) 0.55
Killip class >1 1 (1%) 1 (2%) 0.92
Summed ST deviation (mm) 15±12 17±9 0.27
Anterior myocardial infarction 23 (38%) 26 (38%) 0.99
Q wave 32 (53%) 42 (62%) 0.24
Multi (>1) vessel disease 23 (38%) 28 (41%) 0.74
TIMI flow pre PCI <2 38 (67%) 51 (75%) 0.31
TIMI flow post PCI <2 1 (2%) 2 (3%) 0.67
Symptoms-to-admission (min) 158±131 163±201 0.87
Symptoms-to-balloon (min) 286±146 257±211 0.38
Symptoms-to-arrival (min) 158±131 163±201 0.87
Door-to-balloon (min) 125±59 94±54 0.003
Time-to-treatment (min) 286±146 257±211 0.39
Table 1 Patient characteristics
CVD cardiovascular disease,
PCI percutaneous coronary
intervention, CABG coronary
artery bypass grafting, TIMI
thrombolysis in myocardial
infarction
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Scintigraphic Data and 5-Year Clinical Outcome
We investigated if parameters from a 99mTc-sestamibi
SPECT on day 3 were related to the combined endpoint
of death or re-MI at 5-year follow-up. However, in
univariate and multivariate Cox regression analyses, none
of the assessed scintigraphic parameters were related to this
combined endpoint. Only a higher Killip class and Q wave
infarction were related (Table 3).
Discussion
The results indicate that despite a 31-minute reduction of
door-to-balloon time, scintigraphic parameters and 5-year
clinical outcome are not considerably affected by
performing off-site PCI. Additionally, in our series, off-
site PCI is equally safe compared with on-site PCI.
However, the reduction in door-to-balloon time did not
result in improved 5-year clinical outcomes with off-site
PCI.
Scintigraphic Data and Long-Term Clinical Outcome
Scintigraphic parameters did not predict 5-year clinical
outcomes. This is in contrast to the results of Spinelli et al.
who found that dysfunctional but viable myocardium with
preserved systolic thickening was the strongest predictor of
cardiovascular risk [10]. However, the infarct size in their
study was quite small, while larger infarcts, i.e. >12% of LV
myocardial mass correlate to mortality [11]. Clinical factors
that independently predicted 5-year clinical outcomes in our
series were a higher Killip class and Q-wave myocardial
infarction.
Table 3 Univariate and multivariate analyses for the long-term combined endpoint (death/re-MI)
Crude hazard ratio and 95% CI Multivariate adjusted hazard ratio and 95% CI P value
Off-site centre 1.2 (0.53–2.6) 1.3 (0.56–3.2) 0.51
Age (years) 1.03 (0.99–1.06) 1.03 (0.99–1.1) 0.14
Men 1.0 (0.42–2.4) –
Diabetes mellitus 3.2 (0.97–11) 2.5 (0.63–9.7) 0.20
Smoker 1.3 (0.72–2.2) 1.3 (0.74–2.3) 0.36
Hypertension 1.3 (0.54–2.9) –
Family history of CVD 0.60 (0.26–1.4) 0.76 (0.31–1.8) 0.54
Previous PCI 0.05 (0–600) –
Previous CABG 1.1 (0.15–8.3) –
Killip class >1 2.8 (0.38–21) 25.1 (2.0–315) 0.013
Summed ST deviation (mm) 1.03 (0.72–1.5) –
Anterior myocardial infarction 1.3 (0.60–2.9) 1.4 (0.49–4.0) 0.54
Q wave 3.1 (1.2–8.4) 3.4 (1.02–11.2) 0.046
Multi-vessel disease (>1) 1.1 (0.49–2.4) –
TIMI flow pre PCI <2 1.2 (0.51–2.8) –
TIMI flow post PCI <2 0.46 (0.06–3.4) 0.75 (0.08–7.3) 0.80
Symptoms-to-admission (h) 1.06 (0.96–1.16) 0.94 (0.61–1.5) 0.79
Door-to-balloon (h) 1.01 (0.68–1.5) –
Time-to-treatment (h) 1.05 (0.96–1.15) 1.09 (0.71–1.7) 0.69
LVESV (10 ml) 1.02 (0.90–1.2) –
LVEDV (10 ml) 1.01 (0.91–1.1) –
LVEF (%) 1.0 (0.97–1.03) –
Infarct extent (%) 1.02 (0.99–1.04) 1.0 (0.82–1.2) 0.97
SRS 1.02 (0.99–1.05) 1.03 (0.80–1.3) 0.83
SMS 1.01 (0.99–1.03) 1.03 (0.95–1.1) 0.50
STS 1.01 (0.99–1.03) 0.95 (0.86–1.1) 0.35
Variables with a p value <0.5 in univariate analysis and all scintigraphic variables were included in the multivariable model
MI myocardial infarction, LVESV left ventricular end-systolic volume, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection
fraction, SRS summed rest score, SMS summed motion score, STS summed thickening score
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On-Site Versus Off-Site PCI: Influence on Clinical
and Scintigraphic Parameters
In spite of a reduced door-to-balloon time, off-site PCI
did not result in a significantly different infarct size or
long-term clinical outcomes, although the STS was
smaller in on-site PCI. However, the 31-min reduction
in door-to-balloon time in off-site PCI was relatively
short. Myocardial salvage is particularly pronounced
within the first 2 h of infarction and levels off in the
ensuing hours [12]. Given the average time-to-treatment
of 4.5 h, this may have obscured a potential benefit,
particularly as few patients (10%) were treated within this
early timeframe.
Door-to-Balloon Time: Influence on Clinical
and Scintigraphic Parameters
Earlier large studies demonstrated that time-to-treatment is
important in salvaging acutely jeopardised myocardium
when performing a primary PCI [5,13]. However, in our
study, a relationship between timing of reperfusion and
infarct size or 5-year clinical outcome could not be
established. This is similar to results from smaller studies
that provided conflicting results with the larger studies
[6,14].
Limitations
The number of investigated patients was relatively small
and may explain why the impact of time on infarct size or
long-term clinical outcome was not apparent. In addition,
this study was performed in an area with a good
infrastructure and relatively small inter-hospital transfer
distances. In a more remote area, differences might actually
become apparent.
The 99mTc-sestamibi SPECT might have been too early,
since early cardiac remodelling after the acute phase takes
several weeks before a final equilibrium has been reached
[15]. Therefore, it might have been more appropriate to
perform this scan at a later stage, e.g. 6 weeks after the
event.
Conclusion
After a mean follow-up of 5.8 years, long-term clinical
outcomes and scintigraphic parameters were not affected by
performing off-site PCI, despite a 31-min reduction of door-
to-balloon time. Parameters from rest gated 99mTc-sestamibi
SPECT on day 3 after MI did not predict long-term clinical
outcomes.
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